Iespējams, integrāzes inhibitori paaugstina aptaukošanās risku
Apskatīt komentārus (0)
13.01.2019
Kā parādīja novērojumi, pacientiem, kuri lietoja integrāzes inhibitorus, divu gadu laikā svars pieauga vidēji no viena līdz četriem kilogramiem kopš terapijas sākuma. Pacientiem, kuri uzņēma raltegravīru shēmā ar tenofovīru/emtricitabīnu, bija ievērojami lielāka tendence iegūt lieko svaru nekā tiem, kuri saņēma darunavīru vai atazanavīru. Tāpat cilvēkiem, kas lietoja dolutegravīru, svars pieauga vairāk nekā tiem, kuri lietoja efavirenzu.
Vēl vienā pētījumā dolutegravīrs tika salīdzināts ar jaunāko integrāzes inhibitoru biktegravīru abu grupu dalībniekiem svars 96 nedēļās vidēji pieauga vairāk nekā par trim kilogramiem. Turklāt cilvēki, kuri lietoja tenofovīra alafenamīdu (TAF), vidēji vairāk pieņēmās svarā, uzņemot integrāzes inhibitorus, nekā tie, kuri uzņēma tenofovīra dizoproksilu (TDF).
Pie tam tiem, kuri uzņēma dolutegravīru komplektā ar abakavīru, svars pieauga vairāk nekā tiem, kas terapijā uzņēma dolutegravīru ar tenofovīru (TDF).
Tomēr neviens no pētījumiem pagaidām nepierāda, ka integrāzes inhibitori izraisa svara pieaugumu vairumam vai arī visiem pacientiem.
**************************
Source: «Do integrase inhibitors raise the risk of obesity?» | Keith Alcorn | http://www.aidsmap.com/Do-integrase-inhibitors-raise-the-risk-of-obesity/page/3415242/ |
<... People who take an integrase inhibitor as part of their HIV treatment appear to gain more weight than others after starting treatment and the trend is more common in women and black people, according to a review of observational studies and clinical trials published in the Journal of Virus Eradication. Its authors are Dr Andrew Hill of the University of Liverpool, Dr Laura Waters of the Mortimer Market Centre and Professor Anton Pozniak of Chelsea and Westminster Hospital, both in London.
Gaining a modest amount of weight after starting antiretroviral treatment is common, but the authors are concerned that integrase inhibitor treatment may be linked to unusual weight gain and that more evidence is needed to show whether weight gain is a common side-effect of integrase inhibitors, who is at higher risk and whether specific regimens are more likely to lead to the side-effect.
Four integrase inhibitors are currently approved for use in people living with HIV: raltegravir (Isentress), dolutegravir (Tivicay, also in Triumeq and Juluca), elvitegravir (in Stribild or Odefsey) and bictegravir (in Biktarvy). Integrase inhibitor-based treatment is recommended as a preferred option for first-line HIV treatment in many countries. The first integrase inhibitor, raltegravir, was approved in 2007.
Several randomised clinical trials comparing an integrase inhibitor to a boosted protease inhibitor have shown greater weight gain in people receiving an integrase inhibitor. Studies have typically reported median gains of between 1kg and 4kg over one to two years of follow-up. ...>
Atpakaļ